Zanichelli, Andrea http://orcid.org/0000-0002-7512-4644
Farkas, Henriette http://orcid.org/0000-0003-2929-1721
Bouillet, Laurance
Bara, Noemi
Germenis, Anastasios E.
Psarros, Fotis
Varga, Lilian
Andrási, Noemi
Boccon-Gibod, Isabelle
Castiglioni Roffia, Marco
Rutkowski, Michal
Cancian, Mauro
Funding for this research was provided by:
Università degli Studi di Milano
Article History
Accepted: 25 February 2021
First Online: 31 March 2021
Declarations
:
: The competent board (Comitato Etico Indipendente Milano Area A, Registro Sperimentazioni n. 2015/ST/253) of the coordinating center in Milan approved the registry protocol as an investigator-initiated observational study in 2016 and the amended version on February 27, 2017.
: The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
: AZ received speaker/ consultancy fees from BioCryst, CSL Behring, Pharming, and Takeda. HF received honoraria and travel grants from CSL Behring, Shire/Takeda, Swedish Orphan Biovitrum, Octapharma, Kalvista and Pharming; and/or served as a consultant for these companies and has participated in clinical trials/registries for BioCryst, CSL Behring, Pharming, Kalvista and Shire. LB received honoraria and travel grants from CSL Behring, Novartis, Pharming and Takeda, and her institute received research funding from CSL Behring, Novartis and Takeda. NB received travel grants from CSL Behring, Shire-Takeda, Pharming Group NV, Chiesi Pharmaceuticals GmbH and speaker fees from Shire-Takeda and Glaxo-Smith Klein. AEG received research grants from Shire-Takeda. FP received speaker fees from Shire-Takeda, Novartis, CSL Behring. IB-G- reports grants, personal fees and non-financial support from Shire-Takeda and Biocryst, and non-financial support from Pharming and CSL Behring. MC received travel grants from CSL Behring, Menarini, Novartis, Shire-Takeda and consultancy fees from Biocryst, CSL Behring, Shire-Takeda. His Institution received scientific grants from CSL Behring and Shire-Takeda. LV, NA, MR, and MCR report no conflicts of interest.
: Patients gave a written informed consent.
: Patients gave a written informed consent.